AR074341A1 - Derivados heterociclicos de isoindol, inhibidores de proteinasas bace, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de patologias relacionadas a deficiencias cognitivas, tales como alzheimer. - Google Patents
Derivados heterociclicos de isoindol, inhibidores de proteinasas bace, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de patologias relacionadas a deficiencias cognitivas, tales como alzheimer.Info
- Publication number
- AR074341A1 AR074341A1 ARP090104400A ARP090104400A AR074341A1 AR 074341 A1 AR074341 A1 AR 074341A1 AR P090104400 A ARP090104400 A AR P090104400A AR P090104400 A ARP090104400 A AR P090104400A AR 074341 A1 AR074341 A1 AR 074341A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- alkenyl
- aryl
- alkynyl
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical class C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 title 1
- 102100021257 Beta-secretase 1 Human genes 0.000 title 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 title 1
- 230000007812 deficiency Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 208000024827 Alzheimer disease Diseases 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 206010012289 Dementia Diseases 0.000 abstract 3
- -1 SO2R2 Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010036631 Presenile dementia Diseases 0.000 abstract 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11463408P | 2008-11-14 | 2008-11-14 | |
| US13976708P | 2008-12-22 | 2008-12-22 | |
| US22165309P | 2009-06-30 | 2009-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074341A1 true AR074341A1 (es) | 2011-01-12 |
Family
ID=42170158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104400A AR074341A1 (es) | 2008-11-14 | 2009-11-13 | Derivados heterociclicos de isoindol, inhibidores de proteinasas bace, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de patologias relacionadas a deficiencias cognitivas, tales como alzheimer. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8030500B2 (en:Method) |
| EP (1) | EP2367814A4 (en:Method) |
| JP (1) | JP2012508734A (en:Method) |
| KR (1) | KR20110091540A (en:Method) |
| CN (1) | CN102282140A (en:Method) |
| AR (1) | AR074341A1 (en:Method) |
| AU (1) | AU2009314664A1 (en:Method) |
| BR (1) | BRPI0921879A2 (en:Method) |
| CA (1) | CA2743938A1 (en:Method) |
| CL (1) | CL2011001098A1 (en:Method) |
| CO (1) | CO6362004A2 (en:Method) |
| CR (1) | CR20110255A (en:Method) |
| CU (1) | CU20110106A7 (en:Method) |
| DO (1) | DOP2011000138A (en:Method) |
| EA (1) | EA201190020A1 (en:Method) |
| EC (1) | ECSP11011051A (en:Method) |
| IL (1) | IL212590A0 (en:Method) |
| MX (1) | MX2011004918A (en:Method) |
| NI (1) | NI201100099A (en:Method) |
| PE (1) | PE20110875A1 (en:Method) |
| TW (1) | TW201020244A (en:Method) |
| UY (1) | UY32241A (en:Method) |
| WO (1) | WO2010056196A1 (en:Method) |
| ZA (1) | ZA201104396B (en:Method) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1942105B8 (en) | 2005-10-25 | 2014-08-13 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivative |
| TW200815349A (en) * | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
| RU2476430C2 (ru) | 2007-04-24 | 2013-02-27 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина, замещенные циклической группой |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| EP2485591B1 (en) | 2009-10-08 | 2016-03-23 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| MX2012006491A (es) | 2009-12-11 | 2012-07-03 | Shionogi & Co | Derivados de oxazina. |
| UY33376A (es) * | 2010-05-12 | 2011-12-30 | Astrazeneca Ab | Sal de tipo hemifumarato |
| EP2601197B1 (en) | 2010-08-05 | 2014-06-25 | Amgen Inc. | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
| CN103261199A (zh) | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
| JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| US20120165346A1 (en) * | 2010-12-22 | 2012-06-28 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| US10707526B2 (en) | 2015-03-27 | 2020-07-07 | New Dominion Enterprises Inc. | All-inorganic solvents for electrolytes |
| CN105272884B (zh) * | 2015-11-02 | 2017-05-24 | 浙江大学 | 一种邻氰基二苯甲酮衍生物的制备方法 |
| US10707531B1 (en) | 2016-09-27 | 2020-07-07 | New Dominion Enterprises Inc. | All-inorganic solvents for electrolytes |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605642A (en) | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
| US5063245A (en) | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
| DK0730643T3 (da) | 1993-10-27 | 2001-05-14 | Elan Pharm Inc | Transgene dyr, som huser APP-allel med svensk mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| DE4419849A1 (de) | 1994-06-07 | 1995-12-14 | Hoechst Ag | Isoindolinpigmente |
| PL181895B1 (pl) | 1994-06-16 | 2001-10-31 | Pfizer | Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL |
| DE19516804A1 (de) | 1995-05-08 | 1996-11-14 | Hoechst Ag | Isoindolinpigmente auf Basis von Aminochinoxalindionen |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| US6211235B1 (en) | 1996-11-22 | 2001-04-03 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting β-amyloid peptide release and/or its synthesis |
| GB9701684D0 (en) | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
| JP2001514260A (ja) | 1997-09-02 | 2001-09-11 | デュポン ファーマシューティカルズ カンパニー | Ｃｎｓおよびストレス関連疾患の治療に有用な、副腎皮質刺激ホルモン放出ホルモン拮抗剤としての、複素環基が置換した環縮合ピリジン類およびピリミジン類 |
| US5981168A (en) | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| DK1115874T3 (da) | 1998-09-24 | 2009-04-20 | Pharmacia & Upjohn Co Llc | Alzheimer's sygdom-sekretase |
| US6245884B1 (en) | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
| AU4000900A (en) | 1999-02-10 | 2000-08-29 | Elan Pharmaceuticals, Inc. | Beta-secretase enzyme compositions and methods |
| WO2000058479A1 (en) | 1999-03-26 | 2000-10-05 | Amgen Inc. | Beta secretase genes and polypeptides |
| JP2003502342A (ja) | 1999-06-15 | 2003-01-21 | エラン ファーマスーティカルズ インコーポレイテッド | ベータ−セクレターゼのスタチン誘導テトラペプチド阻害剤 |
| ATE482233T1 (de) | 1999-06-28 | 2010-10-15 | Oklahoma Med Res Found | Inhibitoren des memapsin 2 und ihre verwendung |
| ATE431419T1 (de) | 1999-09-23 | 2009-05-15 | Pharmacia & Upjohn Co Llc | Alzheimer krankheit sekretase, app (amyloid vorlaüfer-protein) substrate dafür und verwendungen |
| GB9924957D0 (en) | 1999-10-21 | 1999-12-22 | Smithkline Beecham Plc | Novel treatment |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| CA2410972A1 (en) | 2000-06-30 | 2002-01-10 | Elan Pharmaceuticals, Inc. | Compounds to treat alzheimer's disease |
| US6696488B2 (en) | 2000-08-11 | 2004-02-24 | The Brigham And Women's Hospital, Inc. | (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production |
| US7630838B2 (en) | 2000-09-22 | 2009-12-08 | American Home Products Corporation | Method for identifying agents that interact with beta-site APP cleaving enzyme (BACE) |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| WO2005058311A1 (en) | 2003-12-15 | 2005-06-30 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| AU2005230878A1 (en) | 2004-03-30 | 2005-10-20 | Merck & Co., Inc. | 2-aminothiazole compounds useful as aspartyl protease inhibitors |
| WO2005123672A2 (en) | 2004-06-14 | 2005-12-29 | Takeda San Diego, Inc. | Kinase inhibitors |
| TW200602045A (en) | 2004-06-16 | 2006-01-16 | Wyeth Corp | Amino-5, 5-diphenylimidazolone derivatives for the inhibition of β-secretase |
| AU2005264917A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| KR20070089908A (ko) | 2004-09-21 | 2007-09-04 | 아더시스 인코포레이티드 | Ｃｒｔｈ２ 수용체 길항작용을 나타내는 인돌 아세트산 및이의 용도 |
| US20090221579A1 (en) | 2004-10-15 | 2009-09-03 | Jeffrey Scott Albert | Substituted Amino-Compounds and Uses Thereof |
| WO2006041405A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-pyrimidones and uses thereof |
| US20080287399A1 (en) | 2004-12-14 | 2008-11-20 | Astrazeneca Ab | Substituted Aminopyridines and Uses Thereof |
| CN101103034A (zh) | 2005-01-14 | 2008-01-09 | 惠氏公司 | 抑制β-分泌酶的氨基-咪唑酮 |
| ES2400287T3 (es) | 2005-03-14 | 2013-04-08 | High Point Pharmaceuticals, Llc | Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa |
| JP2008543841A (ja) | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | 大環状複素環式アスパルチルプロテアーゼインヒビター |
| CA2610815A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| CA2610829A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | The preparation and use of compounds as aspartyl protease inhibitors |
| WO2006138264A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| MX2007016186A (es) | 2005-06-14 | 2008-03-07 | Schering Corp | Preparacion y uso de inhibidores de proteasas. |
| CA2610828A1 (en) * | 2005-06-14 | 2006-12-28 | Schering Corporation | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| AU2006266167A1 (en) | 2005-06-30 | 2007-01-11 | Wyeth | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| ATE550338T1 (de) | 2005-07-18 | 2012-04-15 | Merck Sharp & Dohme | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit |
| US7601751B2 (en) | 2005-09-01 | 2009-10-13 | Bristol-Myers Squibb Company | Indole acetic acid acyl guanidines as β-secretase inhibitors |
| EP1942105B8 (en) | 2005-10-25 | 2014-08-13 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivative |
| JP2009513656A (ja) | 2005-10-27 | 2009-04-02 | シェーリング コーポレイション | 複素環式アスパルチルプロテアーゼインヒビター |
| CN101351460A (zh) | 2005-10-31 | 2009-01-21 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
| JP2009515949A (ja) | 2005-11-15 | 2009-04-16 | アストラゼネカ・アクチエボラーグ | 新規な２−アミノピリミジノン誘導体およびそれらの使用 |
| EP1951681A4 (en) | 2005-11-15 | 2011-06-15 | Astrazeneca Ab | NEW 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE |
| JP2009515951A (ja) | 2005-11-15 | 2009-04-16 | アストラゼネカ・アクチエボラーグ | 新規な２−アミノピリミジノンまたは２−アミノピリジノン誘導体およびそれらの使用 |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| US20090176850A1 (en) | 2005-11-21 | 2009-07-09 | Astrazeneca Ab | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia |
| TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| AR058381A1 (es) | 2005-12-19 | 2008-01-30 | Astrazeneca Ab | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica |
| US20090099217A1 (en) | 2006-04-05 | 2009-04-16 | Astex Therapeutics Ltd. | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies |
| TW200808751A (en) | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
| CN101484429A (zh) | 2006-06-12 | 2009-07-15 | 先灵公司 | 杂环的天冬氨酰基蛋白酶抑制剂 |
| TW200815449A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds II |
| TW200808796A (en) | 2006-06-14 | 2008-02-16 | Astrazeneca Ab | New compounds III |
| TW200815443A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds I |
| TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| WO2008063114A1 (en) | 2006-11-20 | 2008-05-29 | Astrazeneca Ab | Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia |
| TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| WO2008076044A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5, 5-diaryl-imidazol-4-ones |
| TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| TW200902503A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| WO2009005471A1 (en) | 2007-07-05 | 2009-01-08 | Astrazeneca Ab | Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors |
| WO2009005470A1 (en) * | 2007-07-05 | 2009-01-08 | Astrazeneca Ab | Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors |
| US20100125081A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 574 |
| US20100125087A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 575 |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| EP2485591B1 (en) | 2009-10-08 | 2016-03-23 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
-
2009
- 2009-11-12 TW TW098138485A patent/TW201020244A/zh unknown
- 2009-11-13 PE PE2011001034A patent/PE20110875A1/es not_active Application Discontinuation
- 2009-11-13 AU AU2009314664A patent/AU2009314664A1/en not_active Abandoned
- 2009-11-13 US US12/618,212 patent/US8030500B2/en not_active Expired - Fee Related
- 2009-11-13 KR KR1020117013516A patent/KR20110091540A/ko not_active Withdrawn
- 2009-11-13 CA CA2743938A patent/CA2743938A1/en not_active Abandoned
- 2009-11-13 JP JP2011536289A patent/JP2012508734A/ja active Pending
- 2009-11-13 MX MX2011004918A patent/MX2011004918A/es not_active Application Discontinuation
- 2009-11-13 AR ARP090104400A patent/AR074341A1/es unknown
- 2009-11-13 EP EP09826375A patent/EP2367814A4/en not_active Withdrawn
- 2009-11-13 WO PCT/SE2009/051295 patent/WO2010056196A1/en not_active Ceased
- 2009-11-13 UY UY0001032241A patent/UY32241A/es not_active Application Discontinuation
- 2009-11-13 BR BRPI0921879A patent/BRPI0921879A2/pt not_active Application Discontinuation
- 2009-11-13 EA EA201190020A patent/EA201190020A1/ru unknown
- 2009-11-13 CN CN2009801545281A patent/CN102282140A/zh active Pending
-
2011
- 2011-04-28 IL IL212590A patent/IL212590A0/en unknown
- 2011-04-28 CO CO11052264A patent/CO6362004A2/es not_active Application Discontinuation
- 2011-05-13 EC EC2011011051A patent/ECSP11011051A/es unknown
- 2011-05-13 NI NI201100099A patent/NI201100099A/es unknown
- 2011-05-13 CL CL2011001098A patent/CL2011001098A1/es unknown
- 2011-05-13 CU CU20110106A patent/CU20110106A7/es unknown
- 2011-05-13 CR CR20110255A patent/CR20110255A/es unknown
- 2011-05-13 DO DO2011000138A patent/DOP2011000138A/es unknown
- 2011-06-13 ZA ZA2011/04396A patent/ZA201104396B/en unknown
- 2011-09-06 US US13/225,707 patent/US20110319426A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| UY32241A (es) | 2010-06-30 |
| IL212590A0 (en) | 2011-07-31 |
| ZA201104396B (en) | 2012-03-28 |
| EP2367814A4 (en) | 2012-07-04 |
| US20100125082A1 (en) | 2010-05-20 |
| CN102282140A (zh) | 2011-12-14 |
| MX2011004918A (es) | 2011-05-30 |
| EP2367814A1 (en) | 2011-09-28 |
| US20110319426A1 (en) | 2011-12-29 |
| CU20110106A7 (es) | 2012-01-31 |
| BRPI0921879A2 (pt) | 2018-10-16 |
| CL2011001098A1 (es) | 2012-02-24 |
| WO2010056196A1 (en) | 2010-05-20 |
| TW201020244A (en) | 2010-06-01 |
| US8030500B2 (en) | 2011-10-04 |
| AU2009314664A1 (en) | 2011-06-23 |
| KR20110091540A (ko) | 2011-08-11 |
| CR20110255A (es) | 2011-07-04 |
| ECSP11011051A (es) | 2011-06-30 |
| CO6362004A2 (es) | 2012-01-20 |
| EA201190020A1 (ru) | 2012-02-28 |
| DOP2011000138A (es) | 2011-06-30 |
| CA2743938A1 (en) | 2010-05-20 |
| NI201100099A (es) | 2012-03-19 |
| PE20110875A1 (es) | 2012-01-11 |
| JP2012508734A (ja) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074341A1 (es) | Derivados heterociclicos de isoindol, inhibidores de proteinasas bace, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de patologias relacionadas a deficiencias cognitivas, tales como alzheimer. | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| MY167264A (en) | Bridged piperidine derivatives | |
| UY32759A (es) | Inhibidores del virus de la hepatitis c | |
| CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| ECSP14013222A (es) | Indazoles | |
| JO3111B1 (ar) | ترايازولوبيريدينات مستبدلة واستخدامها كمثبطات ttk | |
| CU20120084A7 (es) | Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| CR20140143A (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
| AR059314A1 (es) | Derivados de las benzamidas y heteroarenos | |
| MY186165A (en) | New bicyclic dihydroquinoline-2-one derivatives | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR086036A1 (es) | DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5) | |
| JO3040B1 (ar) | ترايازولوبيريدينات | |
| AR083798A1 (es) | Inhibidores selectivos de glucosidasas y sus usos | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| ECSP099216A (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR071512A1 (es) | Derivados de imidazolidinona como inhibidores de 11b-hsd1 | |
| AR077365A1 (es) | Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta | |
| AR081966A1 (es) | Derivados aminoester de alcaloides y composicion medicinal de los mismos | |
| DOP2014000283A (es) | Derivados de pirimidona como agentes antimalaricos | |
| AR099690A1 (es) | Ureas asimétricas p-sustituidas como moduladoras de la actividad de ghrelina | |
| CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |